新型糖肽类抗生素——达巴万星
A new glycopeptide antibiotic——dalbavancin
摘要
随着广谱抗菌药物及免疫抑制剂的使用，人口老龄化社会现象，抗菌药物耐药问题日益严重。和抗菌药物耐药相比，研制一种新型的抗菌药物的速度远远落后于前者。耐药的革兰阳性（G^＋）球菌是导致临床抗感染治疗失败的主要原因之一。
出处
《中国感染控制杂志》
CAS
2011年第2期156-157,104,共3页
Chinese Journal of Infection Control
参考文献10
-
1Lin G,Credito K,Ednie L M,et al.Antistaphylococcal activity of dalbavancin,an experimental glycopeptides[J].Antimicrob Agents Chemother,2005,49(2):770-772.
-
2Lin G,Smith K,Ednie L M,et al.Antipneumococcal activity of dalbavanein compared to other agents[J].Antimicrob Agents Chemother,2005,49(12):5182-5184.
-
3Leighton A,Gottlieb A B,Dorr M B,et al.Tolerability,pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers[J].Antimierob Agents Chemother,2004,48(3):940-945.
-
4Buckwalter M,Dowell J A.Population pharmacokinetic analysis of dalbavancin,a novel lipoglycopeptide[J].J Clin Pharmacol,2005,45(11):1279-1287.
-
5Dowell J A,Gottlieb A B,van Saders C,et al.The pharmacokineties and renal excretion of dalbavandn in healthy subjects[C].Abstracts and Final Program of the 42nd Interscienoe Conference on Antimierobial Agents and Cherootherapy (San Diego).Washington,DC:American Society for Microbiology,2002.
-
6Dowell J,Seltzer E,Stogniew M,et al.Dalvavancin pharmacoldnetcs in subjects with mild ormoderate hepatic impairment[C].In:Program and abstracts of the 43rd Interscienee Conference on Antimierobial Agents and Chemotherapy(Chicago).Washington,DC:American Society for Microbiology,2003.
-
7Candiani G P,Romano G,Cavaleri M,et al.Efficacy of a single dalbavandn dose compared with multiple linezolid doses against penicillin-resistant pneumoeocci in a lobar pneumonia model in the inununocompetent rat[C].In:Program and abstracts of the 41st Interseience Conference on Antimierobial Agents and Chemotherapy.American Society for Microbiology,2001.
-
8Raad I,Darouiehe R,Vazquez J,et al.Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens[J].Clin Infect Dis,2005,40(3):374-380.
-
9Jauregui L E,Babazadeh S,Seltzer E,et al.Randomdzed,double-blind comparison of a once-weekly dalbavancin versus twiowdaily linezolid therapy for the treatment of complicated skin and skin structure infections[J].Clin Infect Dis,2005,41(10):1407-1415.
-
10Seltzer E,Goldberg L,Krause D,et al.Dalbavandn safety in the phase 2/3 clinical development program[J].Critical Care,2008,12(Suppl 2):1186.
-
1王峰,李成建,王建敏.替考拉宁的不良反应[J].中国误诊学杂志,2010,10(25):6295-6295.
-
2石岩,史福锁.替考拉宁临床应用中的不良反应[J].中国医药指南,2014,12(21):89-90. 被引量：1
-
3张伦.抗菌新药替考拉宁市场分析[J].中国制药信息,2005,21(11):36-37. 被引量：3
-
4丛恒.试论麻醉药品经营、使用、管理工作的新动态[J].中国药物依赖性通报,1993,2(2):138-138.
-
5戴华,宋宜志.防止麻醉药品和精神药品在生产过程中流失[J].中南药学,2009,7(10):799-800.
-
6郭月玲,赵子弟,倪慧敏,郑学丽.新型糖肽类抗生素雷莫拉宁研究进展[J].河北化工,2011,34(8):28-31. 被引量：2
-
7白帆,杜小莉.新型糖肽类抗生素达巴万星[J].中国新药杂志,2015,24(13):1441-1444. 被引量：2
-
8陈南华,朱雪波,庄海群.苯唑利啶类的抗菌活性及临床应用[J].山西医药杂志,2002,31(6):475-477.
-
9赵继才.人命大如天[J].中华养生保健,2005,0(9):1-1.
-
10谭玲,刘爱民,孙春华.新糖肽类抗生素达巴万星[J].中国新药杂志,2006,15(12):1020-1023. 被引量：3
